Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500747-21-00

Acronym

81201887MDG3002

Enrollment

120

Registered

2024-11-19

Start date

2025-02-27

Completion date

Unknown

Last updated

2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geographic Atrophy

Brief summary

Ocular and systemic treatment-emergent adverse events., Clinical laboratory and safety assessments., Retinal imaging (FAF, SD-OCT, and CFP) and eye examinations.

Interventions

DRUGPrednison acis 20 mg

DRUGTabletten

DRUGPlacebo to match Prednisone 20mg

DRUG5mg

DRUGJNJ-81201887

DRUGKenacort-A 40

DRUGsuspensie voor injectie 40 mg/ml

DRUGPrednison acis 5 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Ocular and systemic treatment-emergent adverse events., Clinical laboratory and safety assessments., Retinal imaging (FAF, SD-OCT, and CFP) and eye examinations.	—

Countries

Belgium, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026